01—Abstract
Summary
Summary of the 10-K filed February 26, 2020. Cited figures are marked; the original filing is the authoritative source.
Merck & Co., Inc.'s 2019 10-K filing reveals a strong financial performance driven primarily by its Pharmaceutical segment, with notable growth in Keytruda, vaccines like Gardasil/Gardasil 9, and hospital acute care products such as Bridion.
Total sales reached $46.8 billiona, an increase of 11% year-over-year, demonstrating the company's robust market position and the effectiveness of its key growth drivers. The company continues to invest heavily in research and development, with significant progress in its oncology pipeline and regulatory approvals for Keytruda across various cancer types and geographies. Merck also announced plans to spin off its women's health, legacy brands, and biosimilars businesses into a new, independent company to better focus on its core strengths.
This strategic move aims to unlock further value and enhance agility in a dynamic healthcare landscape. The Animal Health segment also showed steady growth, contributing positively to the overall results. Despite overall strong performance, Merck faces ongoing challenges from generic competition, pricing pressures globally, and evolving healthcare regulations.
The company's patent portfolio remains critical, with key products like Januvia and Janumet facing upcoming patent expirations, necessitating continued innovation and pipeline development to offset potential sales declines. The company's financial health remains strong, supported by significant cash flows from operations and a commitment to returning capital to shareholders through dividends and share repurchases.
02—Key points
Key Highlights
- Total sales grew 11% to $46.8 billion in 2019, driven by strong performance in the Pharmaceutical segment, particularly Keytruda and vaccines.
- Keytruda sales surged 55% to $11.1 billion, underscoring its pivotal role in Merck's oncology franchise and growth strategy.
- Gardasil/Gardasil 9 vaccine sales increased by 19% to $3.7 billion, driven by higher demand in Asia Pacific and Europe.
- The company announced plans to spin off its women's health, legacy brands, and biosimilars businesses into a new independent company, expected in the first half of 2021.
- Research and development expenses increased by 1% to $9.9 billion, reflecting continued investment in pipeline development, especially in oncology.
- The Animal Health segment demonstrated steady growth, with sales up 6% to $4.4 billion, boosted by the acquisition of Antelliq.
- Merck returned $10.5 billion to shareholders in 2019 through dividends and share repurchases, highlighting a commitment to capital return.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2019, Merck kept $0.25.
- Revenue$39.12B100.0%
- Cost of revenue−$12.02B30.7%
- Gross profit$27.11B69.3%
- Operating costs−$21.41B54.7%
- Operating income$5.69B14.5%
- Interest, other & tax$4.15B10.6%
- Net income$9.84B25.2%
Where FY2019 revenue went
$39.12B- Cost of revenue: $12.02B, 31% of revenue
- R&D: $9.72B, 25% of revenue
- SG&A: $9.46B, 24% of revenue
- Operating income: $5.69B, 15% of revenue
- Other operating costs: $2.24B, 5.7% of revenue
Kept 15% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2019filed February 26, 2020Financial Statements
FY2019 against FY2018
| Line item | FY2019FY2018 | Change |
|---|---|---|
| Revenue | $39.12B$42.29B | −7.5% |
| Cost of Revenue | $12.02B$13.51B | −11.1% |
| Gross Profit | $27.11B$28.79B | −5.8% |
| R&D Expenses | $9.72B$9.75B | −0.3% |
| SG&A Expenses | $9.46B$10.10B | −6.4% |
| Operating Income | $5.69B— | — |
| Interest Expense | $893.00M$772.00M | +15.7% |
| Net Income | $9.84B$6.22B | +58.2% |
| EPS (Basic) | $3.84$2.34 | +64.1% |
| EPS (Diluted) | $3.81$2.32 | +64.2% |
| Shares Outstanding (Basic) | 2.56B2.66B | −3.7% |
| Shares Outstanding (Diluted) | 2.58B2.68B | −3.7% |
05—Questions
Frequently Asked Questions
What were Merck's key growth drivers in 2019?
Merck's primary growth drivers in 2019 were its oncology franchise, led by Keytruda, its human health vaccines, particularly Gardasil/Gardasil 9, certain hospital acute care products like Bridion, and its Animal Health segment. These areas collectively contributed significantly to the company's overall sales increase.
What is the significance of the planned spin-off of certain businesses?
Merck announced plans to spin off its women's health, legacy brands, and biosimilars businesses into a new, independent company. This strategic move is intended to allow Merck to sharpen its focus on its core growth areas, particularly oncology and vaccines, while enabling the new entity to pursue its own strategic path, potentially unlocking greater value for both companies.
What are the main challenges facing Merck?
Merck faces several challenges, including intense competition from generic and biosimilar products, ongoing pricing pressures globally from managed care organizations and government agencies, and the increasing complexity of healthcare regulations. Additionally, the upcoming patent expirations for key products like Januvia and Janumet require continuous innovation and pipeline development to maintain growth.
How is Merck investing in its future growth?
Merck is significantly investing in research and development, with a strong focus on its oncology pipeline and expanding the indications for Keytruda. The company also actively pursues external innovation through acquisitions and collaborations, as demonstrated by the acquisitions of Peloton Therapeutics and Immune Design in 2019, and Antelliq for its Animal Health business, to strengthen its portfolio and pipeline.
06—Continue